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ABSTRACT
Preterm delivery is the leading cause of perinatal morbidity and mortality worldwide. Despite a
great deal of research into this disease, we still do not understand its pathophysiology. Our treat-
ments for this disease are only marginally effective. Biochemical markers were developed with the
hope of giving us new tools to prevent preterm deliveries. Specifically the hope was that they could
predict which patients were destined to have a preterm delivery. At the present time these markers
perform only satisfactorily at predicting preterm labor. They are expensive and not convenient to
use at present. Perhaps more importantly, though, these markers have given us insight into the
complexities of preterm delivery. Preterm delivery can arise from many different etiologies. This
will lead to research into new treatments as knowledge about preterm delivery is amassed. We
know that any number of pathological processes may be involved in any given patient with preterm
labor. Biochemical markers have the distinct advantage of being able to determine the specific
pathophysiology in a given patient and may allow us to tailor therapy according to the specific
problem. In the future it is likely that a careful search for specific pathophysiology will be the only
way we can treat this disease effectively. For the present time the the biochemical markers will be
used only to predict preterm delivery. Ultrasound measurements of the cervix during the pregnancy
are likely a faster and less expensive way to accomplish that goal. Infect. Dis. Obstet. Gynecol.
5:158-164, 1997. (C) 1997 Wiley-Liss, Inc.
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espite advances in obstetrical and perinatal
care during the past several decades, the rate
of preterm birth has remained unchanged or has
risen. 1,2 Specifically, the extensive use of tocolytic
agents has done little to reduce perinatal morbidity
and mortality from preterm delivery.3,4 Despite its
pivotal role in management, identification of pa-
tients at risk for preterm delivery is difficult. Cur-
rent methods of detecting patients at risk for pre-
term delivery rely on obstetric history, demo-
graphic factors, or premonitory symptoms that are
neither sensitive nor specific,s Biochemical mark-
ers were developed in the hope that they could
predict which patients were destined to have a pre-
term delivery at an early enough interval such that
the delivery could be avoided. Biochemical mark-
ers can be categorized into one of a number groups.
The first group is the inflammatory mediators, or
cytokines, which are produced during preterm la-
bor in response to infection. Fetal fibronectin
(FFN) is a glycoprotein produced by the fetus at
the interface of the placenta and membranes with
the uterine decidua during pregnancy. It can fre-
quently be identified in the lower genital tract se-
cretions in very early pregnancy or late pregnancy.
However, in the early third trimester its presence is
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associated with a high risk of preterm delivery. It is
not clear whether an inflammatory process is re-
sponsible for its production or release into the
lower genital tract. Enzymes such as metallopro-
teinase, phospholipase, sialidase, and protease
measured in the blood or lower genital tract during
pregnancy have been associated with preterm de-
livery. Also endocrinological markers such as estriol
are being studied intensively and may present a
new approach to predicting preterm delivery.
CYTOKINES
The chemical messengers which we produce in re-
sponse to an infection or tissue injury are called
cytokines. These messengers communicate to the
immune system that an infection is present and
initiate a response. Later they modulate the re-
sponse during the healing process. It i estimated
that at least 20% of premature neonates are born to
mothers with intraamniotic infection.6 In the pres-
ence of intraamniotic infection, markedly elevated
levels of inflammatory mediators, or cytokines, are
seen in the amniotic fluid. The cytokines interleu-
kin-l, interleukin-6, and tumor necrosis factor-or
have all been measured in the amniotic fluid.7-1
The inflammatory mediators then stimulate pros-
taglandin synthesis by a variety of uterine tissues.
The prostaglandins then lead to parturition.1-3
Also, elevated cytokine levels in the amniotic fluid
predict preterm labor that is refractory to tocolysis
resulting in preterm delivery.
3 Elevated levels of
cytokines measured non-invasively from the lower
genital tract also predict preterm delivery. 4,1s
Interleukin-6 is a major mediator of the host
response to infection and tissue injury. It is nor-
mally present at low levels in human amniotic fluid
in the second and third trimesters. Spontaneous
labor at term is associated with a modest increase in
the level of interleukin-6.z Intraamniotic infec-
tions, however, are associated with a dramatic in-
crease in amniotic fluid interleukin-6 levels, lz,13
Tumor necrosis factor-or is a cytokine produced
by activated macrophages in response to a variety
of stimuli, including bacterial products, viruses,
and parasites. Endotoxin (lipopolysaccharide), a
component of the cell wall of gram-negative bac-
teria, can itself stimulate decidual cells to produce
tumor necrosis factor.6 No detectable tumor ne-
crosis factor-or was found in the amniotic fluids of
women in the. second trimester, third trimester, or
during normal spontaneous labor.,17 Once again,
in the setting of microbial invasion of the amniotic
cavity, high levels of tumor necrosis factor-or are
found in the amniotic fluid.1 In our center we
found that among patients admitted to the hospital
with threatened preterm labor, women found to
have tumor necrosis factor-or in the lower genital
tract had a greater than six-fold increased risk of
preterm birth.
A new and concerning development is the asso-
ciation of inflammation at the time of parturition
and increased risk of neurological problems. One
study showed an association between multiple cy-
tokines found in the amniotic fluid during preterm
delivery, neonatal brain white matter lesions, and
cerebral palsy.
18 Another study found that expo-
sure of a term infant to intrauterine infection such
as fever or a clinical diagnosis of chorioamnionitis
was associated with a 9 times higher risk of cerebral
palsy.9 These findings in both term and preterm
infants only increase the importance of further
study and understanding of preterm delivery.
FETAL FIBRONECTIN
Fibronectins are large glycoproteins that bind cells
to the extracellular matrix,z They are a family of
ubiquitous proteins found in the plasma and extra-
cellular matrix. Although similar in structure to two
other isoforms of this protein, FFN is distinguished
immunochemically by a unique epitope resulting
from alternate splicing of the primary messenger
RNA transcript. Fetal fibronectin is specific to the
fetus and trophoblast. High concentrations are
found in the amniotic fluid. Immunohistochemical
studies demonstrated FFN throughout the chorion
layer of the fetal membranes, and between the
uterine decidua and intervillous space and the cy-
totrophoblastic cell columns,z
Fetal fibronectin detected in cervical and vagi-
nal secretions during the second and third trimester
have been associated with an increased risk of pre-
term delivery,z,zl In our study we found that
women positive for FFN during threatened pre-
term labor had almost a five-fold increased risk for
preterm birth (p < 0.05). 14 Since FFN is normally
present in amniotic fluid and placental tissue, its
appearance in the lower genital tract is suggestive
of mechanical leakage or inflammation-mediated
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damage to the integrity of the membranes,z Cross-
sectional studies which examined women with
symptoms of preterm labor or rupture of mem-
branes and longitudinal prospective cohort studies
of women at low risk report that the presence of
vaginal or cervical FFN is associated with a four-
fold to nine-fold increased risk of preterm deliver-
y.ZZ,23 Preliminary information shows that FFN can
be recovered from cervical fluid approximately 3
weeks prior to the onset of preterm labor or pre-
term rupture of membranes. 22
Alternatively, the FFN could be released or pro-
duced in large amounts secondary to inflammation
in the chorion, decidua, or cervix. We found an
independent association between inflammatory
markers and FFN. 19 The cytokines may induce the
production of FFN in the fetal membranes or de-
cidua. Interestingly, fibronectin is susizeptible to
proteolytic enzyme activity by both bacteria and
inflammatory cells, z4 Release of proteolytic en-
zymes, either by bacteria or during the processes of
inflammation, could lead to the destruction ofFFN
and disruption of the chorion-decidua interface.
Documentation of associations between specific re-
productive tract infections, virulence factors, or pla-
cental villitis and the presence of FFN would pro-
vide support the idea that infection contributes to
the release of FFN. Identification of a specific
marker for infection-mediated preterm birth may
allow for treatment of the infection and its inflam-
matory responses.
ELASTASE, PROTEASE, PHOSPHOLIPASE
The cervix is composed primarily of collagen and
therefore vulnerable to the effects of bacterial and/
or host-mediated proteolytic enzymes. The action
of exogenous proteases and collagenase on a cervix
could accelerate the processes towards preterm
birth. Microorganisms produce a variety of proteo-
lyric enzymes, including collagenase, elastases, IgA
protease, sialidase, and mucinases. These enzymes
may be involved both in overcoming mucous mem-
brane of the vagina, mucous plug, and other endo-
cervical host defenses and weakening the fetal
membranes,es-z8 Sialidase can break down mucin
and facilitate bacterial attachment (the first step in
establishing bacterial infection). These changes
can lead to disease progression with spread of in-
fection up into the uterus.
Similarly, proteases may act as immunogenic
agents by activating host inflammatory responses.
Release of inflammatory mediators then leads to
prostaglandin activation. Alternately, the proteolyt-
ic enzymes may directly break down cervical col-
lagen and the amniochorion. This then leads to
premature cervical ripening, weakening of fetal
membranes, and premature rupture of the mem-
branes.3z Phospholipase Az (PLAz) may directly
disrupt collagen biosynthesis and participate in cer-
vical ripening and weakening of the fetal mem-
branes,zs PLAz action may involve direct release of
arachidonic acid and subsequent prostaglandin syn-
thesis by maternal tissues,zs
Vaginal fluid levels of sialidase, PLAz, prosta-
glandin E z, and interleukin 1-beta are greatly in-
creased among women with bacterial vaginosis,zs,z8
The role of these putative virulence factors during
pregnancy has not been studied in women. How-
ever, such microbe-produced substances (i.e., col-
lagenase) along with similar enzymes produced of
such virulence factors within the vagina may pre-
dispose to premature cervical ripening, preterm la-
bor, or premature rupture of membranes. An asso-
ciation between virulence-factor presence and
shortened cervical length or funneling would sup-
port these processes.
PROLACTIN
Prolactin is produced by the decidua, maternal ad-
enohypophysis, and fetal pituitary. Decidual pro-
duction of prolactin is induced by the alpha subunit
of human chorionic gonadotropin. Prolactin is then
diffused across the membranes to the amniotic cav-
ity. The role of the prolactin is not clear, but it may
suppress the synthesis of prostaglandins and aug-
ment fetal lung maturity. High levels of prolactin
are found in the amniotic fluid during the second
and third trimesters. Prolactin measured in the
washings of the ectocervix and vaginal fornices pre-
dicts those patients likely to deliver at 34 weeks of
gestation or before, as well as those with shorter
latency to delivery and deliveries with lower birth-
weights,z9 The question of whether prolactin is ac-
tively produced and shed through the cervix or
leaked subclinically through the fetal membranes
remains unresolved.
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ESTRIOL
Considerable information suggests that the fetal
and maternal endocrine systems are involved in the
biology of both term and preterm parturition in
mammalian species. For humans, the association
between the levels of estrogen hormones in blood
and delivery is less clear. Unlike hormone levels
found in serum or urine, salivary fluid levels reflect
only the unbound or free fraction of the hormone.3
For this reason there has been interest in using
salivary estriol (E3) levels to predict delivery. More
than 90% of E3 is derived from fetal sources and its
production increases approximately 3 weeks prior
to the onset of term labor.31 It appears that labor
does not occur spontaneously post-term (after 42
weeks of gestation) without this rise in E3.
3z New
information has shown that salivary E concentra-
tions increase prior to spontaneous preterm labor in
approximately 80% of cases. Increases in E3 have
been associated with induction of many uterine
changes. For example, formation of oxytocin recep-
tors, gap-junction proteins, and prostaglandin syn-
thesis have been reported.
METALLOPROTEINASE
levels of MSAFP in the presence of a structurally
normal fetus is associated with increased risk for
multiple adverse pregnancy outcomes. Among
these studies, a two-fold to ten-fold increase in risk
for preterm birth associated with unexplained el-
evated MSAFP has been noted.4-6 Preterm rup-
ture of membranes, intrauterine growth retarda-
tion, stillbirth, pregnancy-induced hypertension,
and placental abruption are also increased signifi-
cantly.34-6 Why elevated MSAFP is related to pre-
term birth is unclear. It is thought that alpha-
fetoprotein is produced in the fetal liver and enters
the maternal serum by crossing the placenta or
through diffusion across the amniochorion.s Pres-
ence of an abnormally high maternal serum level
may reflect placental dysfunction or damage to the
maternal-placental barrier.7 Evidence at delivery
of either placental inflammation (villitis) or old
thrombosis has been demonstrated among up to
70% ofwomen who had an elevated MSAFP in the
second trimester.3s The etiology of such early pla-
cental damage remain unclear; however, chronic
infection and inflammation of the uterine lining
(decidua) or acute ascending infection may play a
role.
Metalloproteinases are a family of enzymes includ-
ing collagenase, gelatinase, and stromelysins.
These enzymes are produced by the body to aid in
the breakdown of tissues. There are naturally oc-
curring inhibitors of these enzymes called tissue
inhibitors of metalloproteinases. During preg-
nancy, high levels of this inhibitor are found in the
amniotic fluid. On the other hand, the serum levels
are lower than in the nonpregnant state.3 Most
importantly, serum levels of the inhibitor increase
significantly prior to both term and preterm labor
states.33
ELEVATED MATERNAL SERUM
ALPHA-FETOPROTEIN
Screening all pregnant women for the maternal se-
rum level of alpha-fetoprotein (MSAFP) is well es-
tablished to help detect the presence of neural
tube defects and aneuploidy.4 Approximately 2-
3% of all women screened have elevated MSAFP
levels which can not be explained by correction of
gestational age assessment, presence of multiple
gestations, fetal death, or presence of an anomalous
fetus.4 Increasing information suggests that high
CERVICAL SONOGRAPHY AND
PRETERM DELIVERY
Ultrasound evaluation of the cervix is being used
increasingly to assist in the management of preterm
labor and as a screen to identify patients at high
risk for preterm delivery. We understand that data
obtained by measuring the cervix with the tranab-
dominal approach is far less reliable than that ob-
tained from the transvaginal approach. Transvagi-
nal ultrasound of the cervix is being used in three
clinical settings in regard to preterm delivery. It is
being used during the management ofwomen with
suspected cervical incompetence, in screening pro-
grams of women at high risk for evidence of cervi-
cal shortening, and during evaluation of preterm
labor.39-41 Transvaginal ultrasound offers an objec-
tive method to evaluate the cervix of a woman with
suspected cervical incompetence. For women with
unclear histories for cervical incompetence, such as
second trimester losses with painful dilation, pre-
mature rupture of membranes in the second tri-
mester, or a short cervix on digital exam, transvagi-
nal ultrasound of the cervix adds valuable data to
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help manage the patient. It can assist in the deci-
sion regarding cerclage placement. The cervical
length should remain more than 3 centimeters be-
tween 14 and 20 weeks. If the length is between
2.5 and 3 centimeters, more careful monitoring is
indicated. Patients with questionable histories of
cervical incompetence and a cervical length less
than 2.5 centimeters may benefit from cerclage.
This recommendation is based on the risk of rapid
cervical shortening with loss of the fetus. Studies of
transvaginal ultrasound of the cervix for cervical
length in pregnancy have established norms. Most
studies show that between 10 and 30 weeks gesta-
tion, a cervical length of less than 2.5 centimeters
occurs in less than the tenth percentile.41 More-
over, a short cervix predicts a high risk of preterm
delivery. Women with a history of multiple pre-
term deliveries or multiple gestations may benefit
from monitoring the cervical length during preg-
nancy. Thus far transvaginal ultrasound of the cer-
vix compares favorably with the biochemical mark-
ers in its ability to predict preterm delivery.4z
THE FUTURE OF BIOCHEMICAL MARKERS
chemical markers can we begin to understand the
complex changes that occur during a preterm de-
livery. Once we understand the pathophysiology of
preterm delivery, we can then set about finding the
elusive solution to the problem of preterm deliv-
ery. The biochemical markers may well prove use-
ful in the future to assist us in tailoring therapy for
individual patients with specific problems that are
amenable to medical or surgical therapy. As seen
with the recent findings of increased risk of neu-
rological disease with evidence of inflammation,
they may spur us to use new therapies or, in some
cases, assist in an expedient delivery. In the mean-
time, cervical sonography does have appeal be-
cause it simply looks for an anatomic defect. It is
non-invasive, relatively inexpensive, and predic-
tive of preterm delivery in many cases. It appears
that transvaginal ultrasound of the cervix will per-
form as well as any of the biochemical markers in
predicting preterm delivery. It has an important
role in the management of cervical incompetence
and preterm labor. Ultimately, like the biochemical
markers, even the usefulness of cervical sonogra-
phy will be limited until we understand the patho-
genesis of preterm delivery.
It is clear that the pathophysiology of spontaneous
preterm delivery is poorly understood. It is not
likely that either biochemical markers or cervical
sonography will perfectly predict preterm delivery.
Inflammatory markers and FFN are occasionally
going to be present in the lower genital tracts of
women during uneventful pregnancies. When they
are detected in the presence of uterine contrac-
tions, there is a much higher liklihood of preterm
delivery. Localized, immune-system activation un-
doubtedly takes place in the cervix to prevent vagi-
nal microorganisms from ascending to the uterus.
The initiation and extent of cytokine production in
response to various stimuli is under genetic control
and would be expected to vary between individu-
als.43
None of the biochemical markers has turned out
to be the "solution" to preterm delivery. Substan-
tive improvements in our clinical management and
outcome of preterm labor can only come with un-
derstanding of its pathophysiology. These markers
allow us to objectively determine pathophysiology
in at least some of the mothers who have a preterm
delivery. Only through investigations of the bio-
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